微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 62.93% | -0.23% | 1.16% | 42/159 | -2.82% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 62.21% | -1.75% | 0.51% | 46/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 61.89% | -2.37% | -1.27% | 43/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 62.69% | 0.85% | -0.61% | 46/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 63.07% | 2.11% | -0.38% | 44/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 63.31% | 1.36% | -0.13% | 44/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 63.39% | 1.57% | 1.98% | 41/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 62.16% | -2.15% | 0.64% | 46/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 61.77% | -4.56% | -1.1% | 49/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 62.46% | -2.92% | 0.07% | 50/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 62.42% | -4.58% | -1.75% | 47/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 63.53% | -0.83% | -1.84% | 51/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 64.72% | -0.1% | 0.59% | 49/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 64.34% | -1.01% | -1.64% | 50/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 65.41% | 0.54% | 2.11% | 45/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 64.06% | 0.16% | -1.12% | 56/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 64.78% | 0.35% | -0.32% | 45/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 64.99% | 0.25% | -0.1% | 48/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 65.06% | 0.55% | 1.73% | 38/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 63.95% | -0.62% | -0.93% | 51/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 64.56% | -1.34% | -0.42% | 42/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 64.83% | -1.34% | 0.2% | 43/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 64.7% | -2.5% | 0.54% | 37/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 64.35% | 3.15% | -1.65% | 46/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 65.43% | 3.62% | -0.42% | 32/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 65.71% | 4.02% | -0.98% | 35/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 66.36% | 2.37% | 6.37% | 27/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 62.39% | -0.68% | -1.2% | 46/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 63.15% | -1.25% | -0.04% | 33/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 63.17% | -0.32% | -2.55% | 33/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 64.82% | 0.58% | 3.2% | 30/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 62.82% | 0.78% | -1.76% | 39/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 63.94% | 1.58% | 0.9% | 27/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 63.38% | 1.33% | -1.67% | 25/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 64.45% | 2.75% | 3.4% | 21/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 62.33% | 3.29% | -0.98% | 28/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 62.95% | 3.47% | 0.64% | 20/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 62.55% | 3.06% | -0.29% | 24/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 62.73% | 2.15% | 3.95% | 18/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 60.35% | 2.16% | -0.81% | 27/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 60.84% | 2.69% | 0.24% | 19/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 60.69% | 2.58% | -1.17% | 21/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 61.41% | 5.25% | 3.95% | 18/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |